Jefferies Remains a Buy on Ardelyx (ARDX)

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target from $8 to $15. Earlier, on January 9, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) and raised the price target from $14 to $17.

​Analysts from BITG noted that the positive sentiment is based on the company’s Ibsrela revenue, which grew 73% year-over-year to $274 million in fiscal 2025 and 10% quarter-over-quarter in Q4 2025 to $87 million.

​Notably, the company projects fiscal 2026 Ibsrela revenue between $410 million and $430 million, indicating 50% to 58% year-over-year growth. Peak sales are expected to exceed $1 billion in 2029. BTIG noted that the company ended fiscal 2025 with $265 million in cash. The firm believes that Ardelyx, Inc. (NASDAQ:ARDX) has a robust commercial portfolio and a strong pipeline.

​Similarly, Citi analyst Yigal Nochomovitz on January 8 also raised the price target from $11 to $14, with a Buy rating. The analyst noted that the management’s expectation to reach $1 billion by 2029 exceeds Citi’s estimates, hence the price target update.

​Ardelyx Inc. (NASDAQ:ARDX) discovers, develops, and commercializes medicines to treat unmet medical needs internationally. It offers IBSRELA, which is a minimally absorbed small molecule therapy for patients with IBS with constipation. It also offers XPHOZAH, which is a phosphate absorption inhibitor for adults with chronic kidney disease on dialysis.

While we acknowledge the potential of ARDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARDX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.